Business Wire

TX-ASCEND-PERFORMANCE

15.6.2020 21:13:10 CEST | Business Wire | Press release

Share
Ascend Launches Acteev Protect™ Antimicrobial Technology

Ascend Performance Materials has introduced Acteev Protect™, a breakthrough technology specially formulated to guard against the growth of mildew, fungi and other microbes to keep textiles and nonwoven fabrics fresher for longer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200615005732/en/

The technology is a leap forward in protection for face masks, apparel, upholstery, air filters and more, said Lu Zhang, Ph.D., Ascend’s vice president leading the Acteev launch. “Bacteria, mildew and other microbes growing on fabrics and filters cause the item to break down, discolor and give off unpleasant smells,” she said. “Acteev Protect guards against that microbial growth, keeping the articles clean.”

The technology has been in development for several years, but with the recent shortage of articles resistant to microbial growth, Ascend accelerated the product launch by partnering with independent labs for testing and reallocating resources to scale up production. “The current global scarcity of microbe-resistant materials is not going to end unless manufacturers are able to obtain the right media,” Dr. Zhang said. “We saw a way we could quickly meet those urgent needs with this innovative technology.”

Acteev Protect combines zinc ion technology with polyamide-based woven, nonwoven and knit fabrics. The active zinc ions are embedded into the polymer matrix, providing a long-lasting solution that does not wash away, unlike topical finishes or coatings. The polyamide fabrics are durable yet soft to the skin, and the nonwoven filtration media – available as nanofibers, meltblown and spunbond – efficiently keep out unwanted particles.

The embedded zinc in its ionic form is a powerful inhibitor of bacterial growth, said Vikram Gopal, Ph.D., Ascend’s senior vice president of technology. “Zinc is an essential element needed for bacterial growth, so bacteria readily allows it inside the cell body. But the zinc ion outcompetes other essential elements such as manganese and magnesium and chokes their ingestion channels,” he said. “Without those minerals, the microbes can’t grow or reproduce.”

Other products use silver as an antimicrobial, Dr. Gopal said, but that metal comes with unwanted environmental consequences. “Silver is typically used as a finish or a coating,” he said. “That process is water-intensive, and the excess silver has to be disposed of, eventually ending up in our waterways.”

Zinc, however, is labeled Generally Regarded as Safe by the U.S. Food and Drug Administration.

Additionally, the fabrics feature all the benefits of premium polyamides, which offer more comfort than polypropylene in single-use masks and allows knits and wovens to be dyed, printed on and laundered.

Polyamide 66 wovens and knits have considerable advantages over other types of nylons in garments and other textile applications, said Harrie Schoots, president-elect of the American Association of Textile Chemists and Colorists and a senior business leader of Ascend’s textile business.

“This material resists abrasion and doesn’t pill or shed microfibers. It has a soft hand and excellent drape, and it can be dyed solid or bright colors,” Schoots said. “Uniforms or activewear made with Acteev Protect will be durable and comfortable and can be designed to match current color trends.”

Additionally, these features will last the lifetime of the garment. “Because the zinc ions are embedded during the polymerization process, knit and woven articles made with Acteev Protect stand up to 50 washes or more,” Schoots said.

Ascend is the world’s largest fully integrated producer of polyamide 66 resins and also manufactures fibers and chemicals. Acteev Protect is the company’s first product offering available in ready-to-use fabric form factors. The company plans to extend the line in the coming months to include polyamide 66 fabrics for medical applications and engineered plastics for high-touch surfaces.

For more information, to request a sample or to see performance data, please visit ascendmaterials.com/acteevprotect .

Acteev Protect does not protect users or others against disease-causing bacteria.

About Ascend Performance Materials

Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has nine global locations, including five fully-integrated manufacturing facilities located in the southeastern United States and an engineering plastics compounding facility in Europe, all dedicated to the innovation and safe production. With three of the world’s largest chemical processing facilities, Ascend’s materials form the building blocks for products used in everyday applications from apparel to airbags, cable ties to circuit boards and carpets to car parts. Ascend’s 2,600-person global workforce is committed to making a difference in the communities we serve and leading the development of material solutions that inspire everyone, everywhere, every day.

Together, we’re making a difference.
Together, we’re inspiring everyday.

More information about Ascend can be found at www.ascendmaterials.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye